MK-8719, a Novel and Selective O-GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy
Deposition of hyperphosphorylated and aggregated tau protein in the central [...]
Deposition of hyperphosphorylated and aggregated tau protein in the central [...]
Inhibition of O-GlcNAcase (OGA) has emerged as a promising therapeutic [...]
Advances Novel Tau-directed Strategy for Treating Neurodegenerative Disease Phase 1 [...]
Apr 18, 2016 – Alectos Therapeutics partner Merck, known as MSD [...]
Neurofibrillary tangles (NFTs) made up of aggregated tau protein have [...]
Oct 26, 2014 – Alectos today announced publication of preclinical [...]
BACKGROUND: Amyloid plaques and neurofibrillary tangles (NFTs) are the defining [...]
Regional glucose hypometabolism is a defining feature of Alzheimer disease [...]
Background: The abnormal hyperphosphorylation of the microtubule-associated protein tau plays a [...]
Alzheimer disease (AD) is a growing problem for aging populations [...]